Arcellx
IPOReimagining cell therapy.
Public · Redwood City · Founded 2014 · $375.0M raised
- Headquarters
- Redwood City
- Employees
- 51–200
- Founded
- 2014
- Business Model
- B2B
- Website
- arcellx.com
- Total Funding
- $375.0M
- Last Round
- $150.0M Series AJan 2024
- Rounds
- 4
- Type
- Public
About
Founded in 2015, Arcellx engineers innovative immunotherapies using its proprietary ARC-SparX platform to develop safer, more effective cell therapies. The company focuses on hematologic cancers and autoimmune conditions, with programs in multiple myeloma and other indications.
Summary
Arcellx is a Biopharmaceutical company based in Redwood City, founded in 2014. It has raised $375.0M in total across 4 rounds, most recently a $150.0M Series A round in Jan 2024. Investors include Gilead Sciences, Fairmount and Betta Pharmaceuticals.
Tech & App Stack
6 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2026
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...